Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 14/20 | 0.59 |
| ▸ | NPC1 | O15118 | 3/20 | 0.58 |
| ▸ | RAB9A | P51151 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | ACHE | P22303 | 1/20 | 0.55 |
| ▸ | RAD52 | P43351 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | NPY1R | P25929 | 1/20 | 0.54 |
| ▸ | APP | P05067 | 1/20 | 0.54 |
| ▸ | LTA4H | P09960 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5805661 | 1.00 | HRH3 (0.59) | HRH3NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL5805664 | 1.00 | HRH3 (0.59) | HRH3NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL5796114 | 0.90 | HRH3 (0.58) | HRH3ACHERAD52APP | |
| SCHEMBL5793110 | 0.90 | HRH3 (0.58) | HRH3ACHERAD52APP | |
| SCHEMBL5793105 | 0.90 | HRH3 (0.58) | HRH3ACHERAD52APP | |
| SCHEMBL5793108 | 0.90 | HRH3 (0.58) | HRH3ACHERAD52APP | |
| SCHEMBL5796709 | 0.90 | FAAH (0.55) | HRH3NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL5796707 | 0.90 | FAAH (0.55) | HRH3NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL5796712 | 0.90 | FAAH (0.55) | HRH3NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL5792965 | 0.89 | HRH3 (0.57) | HRH3ACHERAD52APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006024955-A1 | AZABICYCLIC AMINE HISTAMINE-3 RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2006-03-09 | — | — | WO | claimed |
| US-20060047114-A1 | Azabicyclic amine histamine-3 receptor antagonists | PFIZER INC | 2006-03-02 | — | — | US | claimed |
| US-20060047114-A1 | Azabicyclic amine histamine-3 receptor antagonists | PFIZER INC | 2006-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060047114-A1 | Azabicyclic amine histamine-3 receptor antagonists | HRH3, HRH4, HRH2 | HRH3 1/4885NPC1 610/4885RAB9A 346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.